← back to search

Brigitte Neuber

Heidelberg University · DE
Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immunotherapy and Immune Responses, Virus-based gene therapy research, and Viral Infectious Diseases and Gene Expression in Insects.
h-index
22
citations
1,456
works
53
NIH funding
primary concept
email

Recent publications

Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
Leukemia 2024cited by 38position: middledoi
Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial
Journal of Hematology & Oncology 2023cited by 35position: middledoi
Definition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma
International Journal of Molecular Sciences 2023cited by 10position: middledoi
Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV
International Journal of Molecular Sciences 2022cited by 4position: middledoi
Third-Generation Chimeric Antigen Receptor (CAR) T Cells in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) - Results from the Heidelberg Trial 1 (HD-CAR-1 trial)
Blood 2021cited by 3position: middledoi
Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients
Molecular Therapy — Methods & Clinical Development 2020cited by 54position: middledoi
Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR
Cancers 2020cited by 21position: middledoi
Idelalisib for optimized CD19‐specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients
International Journal of Cancer 2019cited by 80position: middledoi
Modulation of B Cells and Homing Marker on NK Cells Through Extracorporeal Photopheresis in Patients With Steroid-Refractory/Resistant Graft-Vs.-Host Disease Without Hampering Anti-viral/Anti-leukemic Effects
Frontiers in Immunology 2018cited by 30position: middledoi
IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells
Cancer Immunology Immunotherapy 2018cited by 26position: middledoi
Influence of Retronectin-Mediated T-Cell Activation on Expansion and Phenotype of CD19-Specific Chimeric Antigen Receptor T Cells
Human Gene Therapy 2018cited by 24position: middledoi
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma
Experimental Hematology 2012cited by 6position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael Schmitt · Leibniz Institute of Photonic Technology9 papers (2018–2024)Carsten Müller‐Tidow · Heidelberg University9 papers (2018–2024)Anita Schmitt · Heidelberg University9 papers (2018–2024)Angela Hückelhoven‐Krauss · University Hospital Heidelberg8 papers (2018–2024)Peter Dreger · Heidelberg Engineering (Germany)7 papers (2018–2024)Maria‐Luisa Schubert · Heidelberg University6 papers (2018–2024)Birgit Michels · University Hospital Heidelberg4 papers (2020–2024)Anthony D. Ho · Mayo Clinic in Arizona4 papers (2012–2024)Leopold Sellner · Takeda (United States)4 papers (2018–2021)Lei Wang · Ministry of Education of the People's Republic of China4 papers (2018–2021)Felix Korell · Heidelberg University3 papers (2021–2024)Ulrike Gern · Heidelberg University3 papers (2018–2020)Jean‐Marc Hoffmann · University Hospital of Zurich3 papers (2018–2019)Alexander Kunz · Paracelsus Medical University3 papers (2020–2021)Sophia Stock · German Cancer Research Center2 papers (2018–2019)Hartmut Goldschmidt · Virginia Cooperative Extension2 papers (2012–2018) · 2 papers (2012–2018)Michael Hundemer · Virginia Cooperative Extension2 papers (2012–2018)Sanmei Wang · Center for Personalized Cancer Treatment2 papers (2018–2019)Susanne Hofmann · University Hospital Heidelberg2 papers (2020–2021)